| abstract |
The present invention provides compounds of the general formula (I):n n n n n n n n Wherein Ar is (a) C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, C 2-4 alkoxyalkoxy, C 1-4 alkylthio, hydroxy, halo, cyano, amino, C 1-4 alkylamino, di (C 2-8 ) alkylamino, C 2-6 alkanoylamino, carboxy, C 2-6 alkoxycarbonyl Phenyl, naphthyl and biphenyl, optionally substituted with; Or optionally substituted phenyl, phenoxy, phenylthio or phenylsulfinyl; Or (b) thienine, benzo [b] thier optionally substituted with C 1-4 alkyl, C 1-4 haloalkyl, halo, C 1-4 alkoxy, optionally substituted phenyl, phenoxy or phenylthio Nil, pyridyl or quinoline; X is C 1-4 alkylene, C 2-4 alkenylene,-(CHR 1 ) m -Q 1- (CHR 2 ) n- , O- (CHR 1 ) j -Q 2 -and-(CHR 1 ) Is selected from -ON = wherein N = residues are attached to a cycloalkene ring, Q 1 is S, SO, SO 2 , NR 3 , CH = NI or CO and Q 2 is O, S, SO, SO 3 or NR 3 , R 1 , R 2 and R 3 are each capital or C 1-4 alkyl, m and n are each an integer of 0 to 4, j is an integer of 1 to 4); p is an integer of 1 or 2; Y is hydrogen, C 1-4 alkyl, C 1-4 alloalkyl, C 1-4 alkoxy, C 2-4 alkoxy alkyl, C 1-4 alkalthio, hydroxy, halo, cyano or amino; Z is hydrogen or C 1-4 alkyl; M is hydrogen, a pharmaceutically acceptable cation or a pharmaceutically acceptable and metabolically cleavable group. The present invention also provides a pharmaceutical composition for treating a disease in need of a 5-lipoxygenase inhibitor in a mammal, comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. Preferred diseases are inflammatory diseases, allergies or cardiovascular diseases. |